After sending blood samples for analysis, a minimum of 10,000 RETs per blood sample are examined for MN, compared to 1,000 to 2,000 using microscopic-scoring techniques. Concurrently, micronuclei are scored in the total RBC population, representing an index of subchronic/chronic treatments. The frequency of RETs is determined as an indication of stem cell toxicity. Results are returned in the form of a GLP report within seven days from receipt of the samples.
The MN endpoint continues to grow in popularity as a genotoxic screen to identify chromosome-damaging agents. Compared to conventional MN methods, the icroFlow Micronucleus Analysis Kit offers more MN data in less time and at a lower cost and with higher precision. When used in conjunction with Stratagenes Big Blue Transgenic Rodent Mutagenesis Assay, a test compound or treatment can be assessed for both mutagenic and clastogenic/aneugenic potential within the same animal.
Matter, B. and Schmid, W. (1971) Mutation Res. 12: 417-425.
Heddle, J. (1973) Mutation Res. 18: 187-190.
MacGregor, J., et al. (1983) In A.W. Hayes, R.C. Schnell and T.S. Miya (Eds.), Developments in the Science and Practice of Toxicology, pp. 555-558. Elsevier, Amsterdam.
Maier, P. and Schmid, W. (1976) Mutation Res. 40: 325-338.
Hayashi, M., Sofuni, T., and Ishidate, M. (1984) Mutation Res.141: 165-169.
Process for Analyzing Clastogenic Agents. Pat